CytoReason, a leader in AI-powered computational disease modeling, announced the expansion of its collaboration with Sanofi for the third time. This multi-year agreement, valued at up to $16 million, further solidifies their partnership. CytoReason technology enables researchers to extract insights from molecular and…
Veeva Systems and BioMarin Pharmaceutical Inc. announced a long-term enterprise agreement that builds upon their long-standing relationship. The expanded partnership will help BioMarin increase speed, agility, operational efficiency, and optimize the healthcare professional and patient experience by further leverag…
MediLink Therapeutics announced that it has entered into a new collaboration and exclusive licensing agreement with Roche for the development and commercialization of YL201, an investigational novel antibody-drug conjugate (ADC) asset targeting B7H3 across numerous solid tumor types. Under the terms of the agreement,…
Eli Lilly and Company and Ventyx Biosciences, Inc. , a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, announced entry into a definitive agreement for Lilly to acquire Ventyx. Ventyx is developing a pipeline of…
Helix, the leading enterprise genomics company, announced a multi-year strategic collaboration with GSK, the global biopharma company. This agreement provides GSK access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas. Helix GenoSphere™ cohorts consist o…
SOPHiA GENETICS, a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools tha…
Amgen announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million. The acquisition adds to Amgen's portfolio an investigati…
Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, announced a strategic collaboration with Sanofi to apply Earendil's discovery platform to multiple autoimmune and inflammatory disease programs. Sanofi will lead the development and worldwide commercializati…
Intelligent Bio Solutions Inc., a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced a new strategic manufacturing partnership with Syrma Johari MedTech Ltd. (“Syrma Johari”), a globally recognized medical device engineering and manufacturing organization with over 45 y…
Insilico Medicine, a world-leading artificial intelligence (AI)-driven drug discovery company, announced a multi-year research and development (R&D) collaboration with Servier, an independent international pharmaceutical company governed by a foundation. This strategic alliance is focused on identifying and develo…
Page 20 of 37